title: Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.
abstract: Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and treatment of prostate cancer. EuK-Subkff-(68)Ga-DOTAGA ((68)Ga-PSMA Imaging & Therapy [PSMA I&T]) is a recently introduced PET tracer for imaging PSMA expression in vivo. Whole-body distribution and radiation dosimetry of this new probe were evaluated.
  
  
  METHODS
  Five patients with a history of prostate cancer were injected intravenously with 91-148 MBq of (68)Ga-PSMA I&T (mean ± SD, 128 ± 23 MBq). After an initial series of rapid whole-body scans, 3 static whole-body scans were acquired at 1, 2, and 4 h after tracer injection. Time-dependent changes of the injected activity per organ were determined. Mean organ-absorbed doses and effective doses were calculated using OLINDA/EXM.
  
  
  RESULTS
  Injection of 150 MBq of (68)Ga-PSMA I&T resulted in an effective dose of 3.0 mSv. The kidneys were the critical organ (33 mGy), followed by the urinary bladder wall and spleen (10 mGy each), salivary glands (9 mGy each), and liver (7 mGy).
  
  
  CONCLUSIONS
  (68)Ga-PSMA I&T exhibits a favorable dosimetry, delivering organ doses that are comparable to (kidneys) or lower than those delivered by (18)F-FDG.
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California Herrmann_K1@ukw.de.
authors.forename: Ken
authors.initials: K
authors.lastname: Herrmann
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Christina
authors.initials: C
authors.lastname: Bluemel
authors.affiliation: Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
authors.forename: Martina
authors.initials: M
authors.lastname: Weineisen
authors.affiliation: Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany.
authors.forename: Margret
authors.initials: M
authors.lastname: Schottelius
authors.affiliation: Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany Scintomics GmbH, Fürstenfeldbruck, Germany; and.
authors.forename: Hans-Jürgen
authors.initials: HJ
authors.lastname: Wester
authors.affiliation: Ahmanson Translational Imaging Division, David Geffen School of Medicine at UCLA, Los Angeles, California.
authors.forename: Johannes
authors.initials: J
authors.lastname: Czernin
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Uta
authors.initials: U
authors.lastname: Eberlein
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Seval
authors.initials: S
authors.lastname: Beykan
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Constantin
authors.initials: C
authors.lastname: Lapa
authors.affiliation: Department of Urology, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Hubertus
authors.initials: H
authors.lastname: Riedmiller
authors.affiliation: Department of Urology, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Krebs
authors.affiliation: Scintomics GmbH, Fürstenfeldbruck, Germany; and.
authors.forename: Saskia
authors.initials: S
authors.lastname: Kropf
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Schirbel
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Andreas K
authors.initials: AK
authors.lastname: Buck
authors.affiliation: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Lassmann
mesh_terms: D000368:Aged; D000954:Antigens, Surface / Q000378:metabolism*; D001853:Bone Marrow / Q000528:radiation effects; D004492:Edetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D043425:Glutamate Carboxypeptidase II / Q000378:metabolism*; D006801:Humans; D007668:Kidney / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000000981:diagnostic imaging*; D011874:Radiometry / Q000379:methods*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012469:Salivary Glands / Q000528:radiation effects; D013154:Spleen / Q000528:radiation effects; D014018:Tissue Distribution; D051598:Whole Body Imaging
chemical_list: D000954:Antigens, Surface; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D009842:Oligopeptides; D019275:Radiopharmaceuticals; C000718244:gallium 68 PSMA-11; D004492:Edetic Acid; C473848:FOLH1 protein, human; D043425:Glutamate Carboxypeptidase II
keywords: 68Ga; PET; PSMA; dosimetry; prostate cancer